

July 1, 2008

**APA DSM-V Work Group Member**

**Name, Degree:** Charles M. Morin, Ph.D.

**Role(s) in Work Group:** Member, Sleep-Wake Disorders Work Group

**Institutional Affiliation(s):** Université Laval, École de Psychologie

**City, State:** Québec, (Quebec), Canada

**Brief Biographical Sketch:**

Charles Morin is Professor of Psychology and Director of the Sleep Research Center at the Université Laval in Quebec City. He received his doctorate degree in clinical psychology from Nova University in Florida (1986) and completed a post-doctoral fellowship (1986-87) at Virginia Commonwealth University, where he remained on the faculty as professor of psychiatry and director of the Sleep Disorders Center from 1987 to 1994. He currently holds a Canada Research Chair on Sleep Disorders and is past President of the Canadian Sleep Society. He is Associate Editor for the journals Sleep and Behavioral Sleep Medicine and is on the editorial board of several other journals. He has published four books and over 150 articles and chapters. His main contributions have been in the development, validation, and dissemination of psychological and behavioral approaches for treating insomnia. His research is funded by the National Institute of Mental Health and by the Canadian Institutes of Health Research.

**UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.**

<b>Non-Profit and Advocacy Organizations</b>	<b>Year(s)</b>	<b>Role</b>
Canadian Sleep Society	2005 2005-2008	President Past-President

The two tables below represent Dr. Charles Morin’s disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Charles Morin has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants and Licensing fees as noted below) will not exceed \$10,000 in any calendar year.

<p><b>KEY NUMBER:</b></p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers’ Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

**DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
Sanofi-Aventis	2005, 2006, 2007	1, 4, 10 (licensing fees for insomnia questionnaire)
Pfizer	2005, 2007	1
Takeda	2005, 2006	4
Eli-Lilly	2007	1, 10 (licensing fees for insomnia questionnaire)
Sepracor	2005, 2006, 2007	1, 4, 10 (licensing fees for insomnia questionnaire)
Neurocrine	2006, 2007	1, 4, 10 (licensing fees for insomnia questionnaire)
Respironics	2007	10 (licensing fees for insomnia questionnaire)
Abbot Lab	2007	10 (licensing fees for insomnia questionnaire)

**DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
Sepracor	2008	1, 10 (licensing fees for insomnia questionnaire)
Sanofi-Aventis	2008	1, 10 (licensing fees for insomnia questionnaire)
Roche-Hoffman	2008	4
Eli-Lilly	2008	10 (licensing fees for insomnia questionnaire)
Organon/Schering-Plough	2008	10 (licensing fees for insomnia questionnaire)